Cargando…

Aberrant Protein Phosphorylation in Cancer by Using Raman Biomarkers

(1) Background: Novel methods are required for analysing post-translational modifications of protein phosphorylation by visualizing biochemical landscapes of proteins in human normal and cancerous tissues and cells. (2) Methods: A label-free Raman method is presented for detecting spectral changes t...

Descripción completa

Detalles Bibliográficos
Autores principales: Abramczyk, Halina, Imiela, Anna, Brożek-Płuska, Beata, Kopeć, Monika, Surmacki, Jakub, Śliwińska, Agnieszka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966530/
https://www.ncbi.nlm.nih.gov/pubmed/31847192
http://dx.doi.org/10.3390/cancers11122017
_version_ 1783488755777142784
author Abramczyk, Halina
Imiela, Anna
Brożek-Płuska, Beata
Kopeć, Monika
Surmacki, Jakub
Śliwińska, Agnieszka
author_facet Abramczyk, Halina
Imiela, Anna
Brożek-Płuska, Beata
Kopeć, Monika
Surmacki, Jakub
Śliwińska, Agnieszka
author_sort Abramczyk, Halina
collection PubMed
description (1) Background: Novel methods are required for analysing post-translational modifications of protein phosphorylation by visualizing biochemical landscapes of proteins in human normal and cancerous tissues and cells. (2) Methods: A label-free Raman method is presented for detecting spectral changes that arise in proteins due to phosphorylation in the tissue of human breasts, small intestines, and brain tumours, as well as in the normal human astrocytes and primary glioblastoma U-87 MG cell lines. Raman spectroscopy and Raman imaging are effective tools for monitoring and analysing the vibrations of functional groups involved in aberrant phosphorylation in cancer without any phosphorecognition of tag molecules. (3) Results: Our results based on 35 fresh human cancer and normal tissues prove that the aberrant tyrosine phosphorylation monitored by the unique spectral signatures of Raman vibrations is a universal characteristic in the metabolic regulation in different types of cancers. Overexpressed tyrosine phosphorylation in the human breast, small intestine and brain tissues and in the human primary glioblastoma U-87 MG cell line was monitored by using Raman biomarkers. (4) We showed that the bands at 1586 cm(−1) and 829 cm(−1), corresponding to phosphorylated tyrosine, play a pivotal role as a Raman biomarker of the phosphorylation status in aggressive cancers. We found that the best Raman biomarker of phosphorylation is the 1586/829 ratio showing the statistical significance at p Values of ≤ 0.05. (5) Conclusions: Raman spectroscopy and imaging have the potential to be used as screening functional assays to detect phosphorylated target proteins and will help researchers to understand the role of phosphorylation in cellular processes and cancer progression. The abnormal and excessive high level of tyrosine phosphorylation in cancer samples compared with normal samples was found in the cancerous human tissue of breasts, small intestines and brain tumours, as well as in the mitochondria and lipid droplets of the glioblastoma U-87 MG cell line. Detailed insights are presented into the intracellular oncogenic metabolic pathways mediated by phosphorylated tyrosine.
format Online
Article
Text
id pubmed-6966530
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69665302020-01-27 Aberrant Protein Phosphorylation in Cancer by Using Raman Biomarkers Abramczyk, Halina Imiela, Anna Brożek-Płuska, Beata Kopeć, Monika Surmacki, Jakub Śliwińska, Agnieszka Cancers (Basel) Article (1) Background: Novel methods are required for analysing post-translational modifications of protein phosphorylation by visualizing biochemical landscapes of proteins in human normal and cancerous tissues and cells. (2) Methods: A label-free Raman method is presented for detecting spectral changes that arise in proteins due to phosphorylation in the tissue of human breasts, small intestines, and brain tumours, as well as in the normal human astrocytes and primary glioblastoma U-87 MG cell lines. Raman spectroscopy and Raman imaging are effective tools for monitoring and analysing the vibrations of functional groups involved in aberrant phosphorylation in cancer without any phosphorecognition of tag molecules. (3) Results: Our results based on 35 fresh human cancer and normal tissues prove that the aberrant tyrosine phosphorylation monitored by the unique spectral signatures of Raman vibrations is a universal characteristic in the metabolic regulation in different types of cancers. Overexpressed tyrosine phosphorylation in the human breast, small intestine and brain tissues and in the human primary glioblastoma U-87 MG cell line was monitored by using Raman biomarkers. (4) We showed that the bands at 1586 cm(−1) and 829 cm(−1), corresponding to phosphorylated tyrosine, play a pivotal role as a Raman biomarker of the phosphorylation status in aggressive cancers. We found that the best Raman biomarker of phosphorylation is the 1586/829 ratio showing the statistical significance at p Values of ≤ 0.05. (5) Conclusions: Raman spectroscopy and imaging have the potential to be used as screening functional assays to detect phosphorylated target proteins and will help researchers to understand the role of phosphorylation in cellular processes and cancer progression. The abnormal and excessive high level of tyrosine phosphorylation in cancer samples compared with normal samples was found in the cancerous human tissue of breasts, small intestines and brain tumours, as well as in the mitochondria and lipid droplets of the glioblastoma U-87 MG cell line. Detailed insights are presented into the intracellular oncogenic metabolic pathways mediated by phosphorylated tyrosine. MDPI 2019-12-13 /pmc/articles/PMC6966530/ /pubmed/31847192 http://dx.doi.org/10.3390/cancers11122017 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abramczyk, Halina
Imiela, Anna
Brożek-Płuska, Beata
Kopeć, Monika
Surmacki, Jakub
Śliwińska, Agnieszka
Aberrant Protein Phosphorylation in Cancer by Using Raman Biomarkers
title Aberrant Protein Phosphorylation in Cancer by Using Raman Biomarkers
title_full Aberrant Protein Phosphorylation in Cancer by Using Raman Biomarkers
title_fullStr Aberrant Protein Phosphorylation in Cancer by Using Raman Biomarkers
title_full_unstemmed Aberrant Protein Phosphorylation in Cancer by Using Raman Biomarkers
title_short Aberrant Protein Phosphorylation in Cancer by Using Raman Biomarkers
title_sort aberrant protein phosphorylation in cancer by using raman biomarkers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966530/
https://www.ncbi.nlm.nih.gov/pubmed/31847192
http://dx.doi.org/10.3390/cancers11122017
work_keys_str_mv AT abramczykhalina aberrantproteinphosphorylationincancerbyusingramanbiomarkers
AT imielaanna aberrantproteinphosphorylationincancerbyusingramanbiomarkers
AT brozekpłuskabeata aberrantproteinphosphorylationincancerbyusingramanbiomarkers
AT kopecmonika aberrantproteinphosphorylationincancerbyusingramanbiomarkers
AT surmackijakub aberrantproteinphosphorylationincancerbyusingramanbiomarkers
AT sliwinskaagnieszka aberrantproteinphosphorylationincancerbyusingramanbiomarkers